JP2024507294A5 - - Google Patents
Info
- Publication number
- JP2024507294A5 JP2024507294A5 JP2023574302A JP2023574302A JP2024507294A5 JP 2024507294 A5 JP2024507294 A5 JP 2024507294A5 JP 2023574302 A JP2023574302 A JP 2023574302A JP 2023574302 A JP2023574302 A JP 2023574302A JP 2024507294 A5 JP2024507294 A5 JP 2024507294A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- approximately
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150301P | 2021-02-17 | 2021-02-17 | |
| US63/150,301 | 2021-02-17 | ||
| PCT/US2022/016571 WO2022177968A1 (en) | 2021-02-17 | 2022-02-16 | Therapeutic methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507294A JP2024507294A (ja) | 2024-02-16 |
| JP2024507294A5 true JP2024507294A5 (https=) | 2025-02-25 |
Family
ID=82931154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574302A Pending JP2024507294A (ja) | 2021-02-17 | 2022-02-16 | 治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250268902A1 (https=) |
| EP (1) | EP4294402A4 (https=) |
| JP (1) | JP2024507294A (https=) |
| KR (1) | KR20230157354A (https=) |
| CN (1) | CN117098538A (https=) |
| AU (1) | AU2022224562A1 (https=) |
| BR (1) | BR112023016459A2 (https=) |
| CA (1) | CA3211215A1 (https=) |
| MX (1) | MX2023009620A (https=) |
| WO (1) | WO2022177968A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026019771A1 (en) * | 2024-07-15 | 2026-01-22 | Celecor Therapeutics, Inc. | Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2804610B1 (en) * | 2012-01-16 | 2018-10-31 | The Rockefeller University | Organic compounds |
| US11684622B2 (en) * | 2018-06-19 | 2023-06-27 | Celecor Therapeutics, Inc. | Deuterated RUC-4 |
-
2022
- 2022-02-16 MX MX2023009620A patent/MX2023009620A/es unknown
- 2022-02-16 CA CA3211215A patent/CA3211215A1/en active Pending
- 2022-02-16 WO PCT/US2022/016571 patent/WO2022177968A1/en not_active Ceased
- 2022-02-16 US US18/277,364 patent/US20250268902A1/en active Pending
- 2022-02-16 CN CN202280025886.8A patent/CN117098538A/zh active Pending
- 2022-02-16 AU AU2022224562A patent/AU2022224562A1/en active Pending
- 2022-02-16 BR BR112023016459A patent/BR112023016459A2/pt unknown
- 2022-02-16 EP EP22756821.9A patent/EP4294402A4/en active Pending
- 2022-02-16 KR KR1020237031649A patent/KR20230157354A/ko active Pending
- 2022-02-16 JP JP2023574302A patent/JP2024507294A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Backon | Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry | |
| JP2020033360A5 (https=) | ||
| Pickles et al. | Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man. | |
| JPS60188323A (ja) | 心筋虚血治療用医薬組成物 | |
| McCrystal et al. | Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl] acridine-4-carboxamide | |
| AU2024219736A1 (en) | Sublingual epinephrine tablets | |
| JP2020510043A5 (https=) | ||
| US4513007A (en) | Method for treating heart disease | |
| KR20210135990A (ko) | 급성 심방 세동의 치료를 위한 설카르딘 투여 | |
| JP2024507294A5 (https=) | ||
| WO2022038191A1 (en) | Combination of apyrase with a p2y12 inhibitor for treating ischemia | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| US6258798B1 (en) | Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin | |
| JP6280106B2 (ja) | Ｎｏ（一酸化窒素）ドナーを用いた動脈新生の誘導 | |
| JP2019507174A (ja) | 心血管疾患におけるリラグルチド | |
| CN113876775A (zh) | 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途 | |
| EP3554483B1 (en) | Reducing side effects of short acting no donors | |
| US20250268902A1 (en) | Therapeutic methods | |
| Adlerfliegel et al. | Sotalol poisoning associated with asystole | |
| JP2957618B2 (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 | |
| RU2018311C1 (ru) | Способ лечения тромбозов и тромбоэмболий | |
| Anderson et al. | Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy: report of two cases | |
| Sinha | Lightning-induced myocardial injury. A case report with management | |
| CN110292637B (zh) | 一种预防、治疗高血压的药物组合物 | |
| Abbou | The efficacy and tolerance of indapamide in essential hypertension: a multi-centre study in 981 patients |